Key result
Pregnancy-related venous thromboembolism, complicating 1 to 2 of 1000 pregnancies, is treated with therapeutic low-molecular-weight heparin for a minimum of 3 months despite a lack of trial data.
Management of pregnancy-related VTE relies on LMWH and multidisciplinary care, highlighting a critical need for dedicated clinical trials in this population.
Answers are grounded in this paper and cite their sources.
LMWH remains standard for pregnancy-related VTE without RCT support; leaves open optimal regimen and duration, warranting dedicated trials.
Venous thromboembolism (VTE) complicates ~ 1 to 2 of 1000 pregnancies, with pulmonary embolism being a leading cause of maternal mortality and deep vein thrombosis an important cause of maternal morbidity, also on the long term. However, a strong evidence base for the management of pregnancy-related VTE is missing. Management is not standardized between physicians, centers, and countries. The management of pregnancy-related VTE is based on extrapolation from the nonpregnant population, and clinical trial data for the optimal treatment are not available. Low-molecular-weight heparin (LMWH) in therapeutic doses is the treatment of choice during pregnancy, and anticoagulation (LMWH or vitamin K antagonists postpartum) should be continued until 6 weeks after delivery with a minimum total duration of 3 months. Use of LMWH or vitamin K antagonists does not preclude breastfeeding. Whether dosing should be based on weight or anti-Xa levels is unknown, and practices differ between centers. Management of delivery, including the type of anesthesia if deemed necessary, requires a multidisciplinary approach, and several options are possible, depending on local preferences and patient-specific conditions.
No takes yet. Share an insight, caveat, or question.
Saskia Middeldorp (2011) conducted a review in Pregnancy-related venous thromboembolism. Low-molecular-weight heparin (LMWH) was evaluated. Pregnancy-related venous thromboembolism, complicating 1 to 2 of 1000 pregnancies, is treated with therapeutic low-molecular-weight heparin for a minimum of 3 months despite a lack of trial data.
Synapse has enriched 10 related papers. Consider them for comparative context: